Background: Clostridium difficile infections pose significant risks to patients in the post-acute
care setting, including prolonged hospitalization and increased mortality. In 2015
and 2016, the facility noted an increase of healthcare acquired Clostridium difficile
cases on its long term acute care (LTAC) and skilled nursing (SNF) units. The purpose
of this study was to determine whether implementing Saccaromyces boulardii, a daily
probiotic supplement, for patients who were receiving intravenous (IV) antibiotics
would reduce the rate of healthcare acquired Clostridium difficile cases.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Infection ControlAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
